Salta al contenuto principale
Home

Dedicated to discovery

  • A proposito di ELGA
    • A proposito di ELGA
    • Carriere
    • Eventi
  • Supporto
    • Progettazione del laboratorio
  • Contatti
  • EN
  • DE
  • ES
  • FR
  • PT
  • EN-US
Home
  • Prodotti
    • PURELAB
      • PURELAB® Dispenser
      • PURELAB® Flex
      • PURELAB® Quest
      • PURELAB® Pharma Compliance
      • PURELAB® Chorus 1 Complete
      • PURELAB® Chorus 1
      • PURELAB® Chorus 2
      • PURELAB® Chorus 3
      • PURELAB® Chorus 2 +
    • CENTRA
      • CENTRA® R60/120
      • CENTRA® R200
      • CENTRA® RDS
    • MEDICA
      • MEDICA® 150
      • MEDICA® 7/15
      • MEDICA® BIOX 2024
      • MEDICA® Pro-R & Pro-RE
      • MEDICA® R200
      • MEDICA® EDI 15/30
      • MEDICA® Pro-LPS
      • MEDICA® Pro EDI 60/120
      • MEDICA® BIOX
      • Hubgrade
    • BIOPURE
      • BIOPURE® 300/600
    • PURENERGY® 30
    • ELGA Gamma Completa di Prodotti
  • Applicazioni
    • Analisi microbiologica
    • Biochimica clinica
    • Colture cellulari
    • Cromatografia liquida
      • High Performance Liquid Chromatography
    • Elettrochimica
    • Gascromatografia
    • Genetica
    • High Performance Liquid Chromatography (HPLC)
    • Immunochimica
    • Requisiti dell'acqua per laboratori generici
    • Spettrofotometria
    • Spettrometria di massa
    • Spettroscopia atomica
  • Tecnologie
    • Carbone attivo
    • Electrodeionization (EDI)
    • Filtrazione
    • Lampada UV
    • Osmosi inversa (RO)
    • PureSure
    • Scambio ionico
  • Impurità nell'acqua
    • Composti inorganici
    • Composti organici
    • Gas disciolti
    • Microorganismi e batteri
    • Partcolati
  • Conoscenza
    • BROSCHÜREN
    • Blog
    • Casi di studio
    • Acqua ultrapura
    • Guide e white paper
  • Dove acquistarli
  • Contattaci
Home
  • Contattaci
  • Prodotti
    • PURELAB
      • PURELAB® Dispenser
      • PURELAB® Flex
      • PURELAB® Quest
      • PURELAB® Pharma Compliance
      • PURELAB® Chorus 1 Complete
      • PURELAB® Chorus 1
      • PURELAB® Chorus 2
      • PURELAB® Chorus 3
      • PURELAB® Chorus 2 +
    • CENTRA
      • CENTRA® R60/120
      • CENTRA® R200
      • CENTRA® RDS
    • MEDICA
      • MEDICA® 150
      • MEDICA® 7/15
      • MEDICA® BIOX 2024
      • MEDICA® Pro-R & Pro-RE
      • MEDICA® R200
      • MEDICA® EDI 15/30
      • MEDICA® Pro-LPS
      • MEDICA® Pro EDI 60/120
      • MEDICA® BIOX
      • Hubgrade
    • BIOPURE
      • BIOPURE® 300/600
    • PURENERGY® 30
    • ELGA Gamma Completa di Prodotti
  • Applicazioni
    • Analisi microbiologica
    • Biochimica clinica
    • Colture cellulari
    • Cromatografia liquida
      • High Performance Liquid Chromatography
    • Elettrochimica
    • Gascromatografia
    • Genetica
    • High Performance Liquid Chromatography (HPLC)
    • Immunochimica
    • Requisiti dell'acqua per laboratori generici
    • Spettrofotometria
    • Spettrometria di massa
    • Spettroscopia atomica
  • Tecnologie
    • Carbone attivo
    • Electrodeionization (EDI)
    • Filtrazione
    • Lampada UV
    • Osmosi inversa (RO)
    • PureSure
    • Scambio ionico
  • Impurità nell'acqua
    • Composti inorganici
    • Composti organici
    • Gas disciolti
    • Microorganismi e batteri
    • Partcolati
  • Conoscenza
    • BROSCHÜREN
    • Blog
    • Casi di studio
    • Acqua ultrapura
    • Guide e white paper
  • Dove acquistarli
  • Contattaci
  • A proposito di ELGA
    • A proposito di ELGA
    • Carriere
    • Eventi
  • Supporto
    • Progettazione del laboratorio
  • Contatti
  • EN
  • DE
  • ES
  • FR
  • PT
  • EN-US
  • Informazioni sull'acqua ultrapura
  • Guide e White Paper
  • Dichiarazioni di conformità legale globale
  • Brevetti
  • Trademarks
  • Impressum
  • Developing Nanoemulsions for Treating Neurodegenerative Diseases
Science of the Future
Clinical & Pharma

Developing Nanoemulsions for Treating Neurodegenerative Diseases

24 Lug 2019
- by Dr Alison Halliday

Brain Scan images

A new study successfully demonstrates the feasibility and therapeutic potential of a new nanoformulation as an effective drug delivery tool to the brain.

Neurodegenerative disorders, including Parkinson’s and Alzheimer’s, are characterised by neuronal death in specific regions of the brain accompanied by deposits of aggregated proteins. With no cures, new treatments are desperately needed that can slow down or stop the progression of these devastating diseases.

To identify new therapeutic targets, researchers are untangling the complex web of pathways involved in disease development – and they are uncovering increasing evidence to suspect a central role for tiny organelles called lysosomes. Packed full of enzymes, these are involved in many everyday cell functions – but it is problems with their role in clearing misfolded and accumulated proteins that are implicated in neurodegenerative disease. As the acidic pH of lysosomes is often perturbed in neurodegenerative disorders, developing ways to correct this could potentially restore normal function.

Restoring the pH Balance of Lysosomes using Acidic Nanoparticles

PLGA1 nanoparticles have recently emerged as a promising carrier for delivery and sustained release of therapeutic agents – due to their biocompatibility, and their ability to protect their cargo from degradation, increasing its half-life. But exploiting the acidic nature of PLGA by using it not only as the carrier but also as the active compound, offers an attractive potential therapeutic opportunity to correct lysosomal dysfunction in neurodegenerative disease.

In previous studies, researchers have shown that acidic nanoparticles (aNPs) of PLGA can restore the function of defective lysosomes – and slow down Parkinson’s disease-related neurodegeneration. But despite these promising initial results, the delivery of aNPs remains challenging and their diffusion is mostly limited to the site of injection directly into the brain.

Developing Nanoemulsions with Improved Brain Delivery and Diffusion 

Developing new formulations that can be delivered by systemic injection into the bloodstream and cross the blood-brain-barrier (BBB) offers a much less invasive route for delivering therapeutics into the brain. Nanoemulsions – dispersions of tiny droplets consisting of oil, surfactant and water – are novel drug delivery systems. Along with improved stability and high loading capacity, they offer additional advantages for carrying hydrophobic agents into the brain – providing extra protection for their load and a natural tendency to cross the BBB.

Promising Initial Results

In a new study, a team of researchers designed an acidic nanoemulsion loaded with PLGA with the aim of enhancing brain diffusion and achieving brain drug delivery after systemic injection.2 The researchers prepared nanoemulsion-based therapies loaded with PLGA and a red fluorescent dye to enable tracking inside the brain – using ultrapure water prepared using an ELGA PURELAB® laboratory water purification system.They carried out a series of experiments showing that these acidic nanoemulsions could restore the acidic lysosomal pH in cellular models of Parkinson’s disease – and directly injecting it into the brain of mice leads to widespread diffusion and internalisation into lysosomes. Finally, they demonstrated that a fraction of their nanoformulation successfully crosses the BBB after systemic delivery and reaches lysosomes in brain cells.

This successful demonstration of the ability of nanoemulsions to cross the BBB, although low in number, suggests this strategy could be highly promising for future drug delivery to the brain. Further nanotechnology-based development will focus on improving the sustained release of PLGA, offering the possibility for future effective new therapies for neurodegenerative diseases.

Why choose ELGA LabWater?

Our history of innovation helps us to research new water purification technologies and techniques. ELGA has been a trusted name in pure and ultrapure water since 1937. We help you to achieve consistent, accurate results. 

 

References

1.  Poly(DL-lactide-co-glycolide)
2.  Prévot et al. Harnessing lysosomal pH through PLGA nanoemulsion as a treatment of lysosomal-related neurodegenerative diseases. Bioconjugate Chemistry 2018      
     doi: 10.1021/acs.bioconjchem.8b00697

 

Dr Alison Halliday
After completing an undergraduate degree in Biochemistry & Genetics at Sheffield University, Alison was awarded a PhD in Human Molecular Genetics at the University of Newcastle. She carried out five years as a Senior Postdoctoral Research Fellow at UCL, investigating the genes involved in childhood obesity syndrome. Moving into science communications, she spent ten years at Cancer Research UK engaging the public about the charity’s work. She now specialises in writing about research across the life sciences, medicine and health.

  • Sales Enquiry
  • Richiedi un Preventivo
  • Technical Support
  • Trova un Partner Approvato

Sales Enquiry

Presso ELGA LabWater, abbiamo offerte interessanti e novità sui nostri prodotti e servizi che speriamo possano interessarti. Utilizzeremo le tue informazioni per prevedere cosa potrebbe piacerti. Tratteremo i tuoi dati con rispetto e puoi trovare tutti i dettagli nella nostra Informativa sulla Privacy.

ELGA LabWater collabora con una rete di Partner Approvati. Per rispondere alle tue domande o richieste, potremmo condividere i tuoi dati di contatto con un Partner Approvato, che potrebbe contattarti direttamente.

Desidero ricevere aggiornamenti da ELGA LabWater e dai Partner Approvati ELGA in base ai miei dati.

Richiedi un Preventivo

Presso ELGA LabWater, abbiamo offerte interessanti e novità sui nostri prodotti e servizi che speriamo possano interessarti. Utilizzeremo le tue informazioni per prevedere cosa potrebbe piacerti. Tratteremo i tuoi dati con rispetto e puoi trovare tutti i dettagli nella nostra Informativa sulla Privacy.

ELGA LabWater collabora con una rete di Partner Approvati. Per rispondere alle tue domande o richieste, potremmo condividere i tuoi dati di contatto con un Partner Approvato, che potrebbe contattarti direttamente.

Desidero ricevere aggiornamenti da ELGA LabWater e dai Partner Approvati ELGA in base ai miei dati.

Technical Support

Presso ELGA LabWater, abbiamo offerte entusiasmanti e novità sui nostri prodotti e servizi che speriamo possano interessarti. Utilizzeremo le tue informazioni per prevedere cosa potrebbe piacerti. Tratteremo i tuoi dati con rispetto e puoi trovare i dettagli nella nostra  Informativa sulla privacy.

ELGA LabWater collabora con una rete di Partner Autorizzati. Per poter rispondere alle tue domande o richieste, potremmo condividere i tuoi dati di contatto con un Partner Autorizzato, che potrebbe contattarti direttamente.

Call us

Can't find what you are looking for?

Support Number
+44 (0)20 3567 7300
United Kingdom Sales
+44 (0)1628 879 704
United States of America Sales
+1 877-315-3542
France Sales
+33 1 40 83 65 00
China Sales
+86 400-616-8882

 

ELGA LabWater Sede Centrale

Lane End Business Park
Lane End, High Wycombe
HP14 3BY
United Kingdom
T: +44 (0) 203 567 7300
F: +44 (0) 203 567 7205

Casi di Studio

  • Abbott Diagnostics
  • DASA Diagnostica Medica
  • NeoDIN Istituto Medico
  • North Staffordshire NHS Trust
  • Scuola Professionale Olsberg

Risorse

  • Informazioni sull'acqua ultrapura
  • Guide e libri bianchi
  • Tecnologie per la purificazione dell'acqua
  • Applicazioni di laboratorio
  • Impurità nell'acqua
  • Latest Blog
  • Che cosa è il carbonio organico totale (TOC)?
  • Che cosa è l'acqua reagente per laboratorio clinico (CLSI)?
  • Purezza dell'acqua - Diversi tipi di acqua pura

© VWS (UK) Ltd. che opera come ELGA LabWater. 2025 - Tutti i diritti riservati.
ELGA è il marchio mondiale dell'acqua di laboratorio di Veolia.

  • Informazioni sull'acqua ultrapura
  • Guide e White Paper
  • Dichiarazioni di conformità legale globale
  • Brevetti
  • Trademarks
  • Impressum
  • Lingua
    • Deutsch
    • English
    • Español
    • Français
    • Italiano
    • Português
    • 日本語
    • 中文
  • Altri Siti Veolia
    • Veolia
    • Veolia Foundation
    • Veolia Water Technologies
Elga Veolia
TOP

© 2017 ELGA Veolia